About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
https://www.soho2019.com/
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
C
The Promising Data on Efficacy of Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed AML
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Courtney D. DiNardo
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Courtney D. DiNardo
19 views
October 18, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Acute Myeloid Leukemia
15:38
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
2019 AML State of the Art Update: How to Treat Newly Diagnosed and S…
Feat.
S. Luger
16:27
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CAR T-Cells in AML: An Effective Therapy Requires Optimization of th…
Feat.
E. Budde
13:57
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Novel Strategies in High Risk AML: Clinical and Molecular Features
Feat.
J. Welch
16:06
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Chemotherapy-Free Approach in Relapsed/Refractory AML: Antibody-Drug…
Feat.
J. DiPersio
15:39
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
All Older AML Patients and Younger Patients with Adverse Biology Sho…
Feat.
D. Pollyea
17:20
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
HMA/Ventoclax vs. 3+7/Standard Induction - Should All Older and Youn…
Feat.
J. Lancet
15:19
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Use of MRD in AML: Determining Method, Acceptable Endpoint and Progn…
Feat.
P. Montesinos
14:52
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
How to Choose a FLT3 inhibitor in AML in 2019: Discussion on Midosta…
Feat.
C. Smith
15:52
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Use of Gemtuzumab in CD33 + AML: Benefit May Be Greatest in Favorabl…
Feat.
R. Walter
08:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin …
Feat.
A. Skwarska
09:44
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
The Promising Data on Efficacy of Mutant IDH1 Inhibitor Ivosidenib (…
Feat.
C. DiNardo
08:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Genome-Wide CRISPR-Cas9 Screen Identifies XPO7 as a Novel Therapeuti…
Feat.
Y. Semba
